According to medical dermatology manufacturer Dermira, the U.S. Food and Drug Administration (FDA) has approved the company's glycopyrronium cloth for the medical treatment of pediatric (9+) and adult patients afflicted by primary axillary hyperhidrosis. The cloth/wipe is provided as a single-use, pre-moistened material sealed in an individual pouch, and is intended for application once daily to healthy armpit skin.
Excessive underarm sweating is a medical condition that, according to Dermira, affects nearly 10 million people in the United States. Historically, treatments have included over-the-counter and prescription options (antiperspirants) or invasive treatments, such as injections. A recent patent application from Unilever also explores an epigenetic approach to reduce sweat production via small-interfering RNA.
Here, the anticholinergic cloth, sold under the trade name Qbrexza, reportedly blocks sweat production by inhibiting the activation of the sweat gland. While not explicitly stated, according to Pubchem, the mechanism of glycopyrrolate is to bind competitively to the muscarinic acetylcholine receptor, inhibiting the action of the acetylcholine neurotransmitter.
The company earned FDA approval following positive results from two Phase 3 clinical trials. Results indicated users experienced a noticeable and sustained reduction in overall sweat production.